Allergan Pharmaceuticals Ireland
🚨 Critical Risk
FEI: 3002806285 • Westport, Co. MAYO • IRELAND
FEI Number
3002806285
Location
Westport, Co. MAYO
Country
IRELANDAddress
Castlebar Road, , Westport, Co. MAYO, Ireland
Critical Risk
FDA Import Risk Assessment
This firm has an extensive history of FDA import refusals with severe violations.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity — AI-assessed (1-10)
- 30% Refusal Volume — Logarithmic scale
- 20% Recency — Decays over 5 years
- 10% Frequency — Refusals per year
© ImportRefusal.com Original Analysis
Violation Summary
UNAPPROVED
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED
It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).
FRNMFGREG
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.
NO ENGLISH
Required label or labeling appears to not be in English in violation of 21 C.F.R. 201.15(c)(1).
NO LICENSE
The article is subject to refusal of admission under section 801(a)(3) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because it appears to be a biological product for which a biologics license is not in effect under the Public Health Service Act, Part F, Subpart 1-Biological Products, Section 351(a), and it is not the subject of an Investigational New Drug application that is in effect. Therefore, it appears to be a new drug under 201(p) of the FD&C Act that it is in violation of section 505(a) of the FD&C Act because it lacks a new drug approval and because it is misbranded under section 502(f)(1)of the FD&C Act because it fails to bear adequate directions for use
NO PMA
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that the device appears to be a Class III device and does not appear to have in effect an approved application for premarket approval pursuant to Section 515 of the Act, or an exemption pursuant to Section 520(g)(1).
DIRECTIONS
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it is a device whose label appears to not bear adequate directions for use.
DRUG GMPS
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that the methods used in and controls used for the manufacture, processing, packing, or holding of drugs and other products do not appear to conform to current good manufacturing practices within the meaning of Section 501(a)(2)(B).
RX DEVICE
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it is a prescription device that appears to not feature a prescription device legend as required by 21 CFR 801.109.
RX LEGEND
The article appears to be a prescription drug without a prescription drug legend as required by Section 503(b)(4).
FDF4APIGMP
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that the methods and controls used in its manufacture and control do not appear to conform to current good manufacturing practices within the meaning of Section 501(a)(2)(B). This finished dosage form drug is made using an Active Pharmaceutical Ingredient from a facility that has been found non-compliant with current Good Manufacturing Practice (see Import Alert 66-40; http://www.accessdata.fda.gov/cms_ia/importalert_189.html). You may submit testimony to provide evidence to overcome the appearance of adulteration. The API source for this finished dosage form drug is:
NO ENGLISH
Required label or labeling appears to not be in English in violation of 21 C.F.R. 801.15(c)(1)
STERILITY
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to have been prepared, packed or held under insanitary conditions whereby it may have been contaminated with filth, or whereby it may have been rendered injurious to health.
NO 510(K)
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it is a post 1976 device for which a Section 510(k)application does not appear to have been determined substantially equivalent or otherwise filed.
Refusal History
| Date | Product | Violations | Division |
|---|---|---|---|
| 11/17/2025 | 58PCZ05ONABOTULINUMTOXINA | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/14/2025 | 58PCK05ONABOTULINUMTOXINA | Division of Southwest Imports (DSWI) | |
| 12/31/2024 | 58PDP05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 12/2/2024 | 66VBY99MISCELLANEOUS PATENT MEDICINES, ETC. | Division of Northern Border Imports (DNBI) | |
| 11/14/2024 | 58PAY05ONABOTULINUMTOXINA | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 10/28/2024 | 58PCY05ONABOTULINUMTOXINA | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 10/11/2024 | 58PAY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 9/27/2024 | 58PCZ05ONABOTULINUMTOXINA | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 8/26/2024 | 58PCZ05ONABOTULINUMTOXINA | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/18/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/18/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/18/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/17/2024 | 58PCZ05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/17/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/17/2024 | 58PDR05ONABOTULINUMTOXINA | 75UNAPPROVED | Division of Northeast Imports (DNEI) |
| 6/17/2024 | 58PCZ05ONABOTULINUMTOXINA | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/12/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/12/2024 | 58PCZ05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/12/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/12/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/12/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/12/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/12/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/12/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/12/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/12/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/12/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/12/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/12/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/12/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/10/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/10/2024 | 58PCZ05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/10/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/10/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/10/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/10/2024 | 58PCZ05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 6/10/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 5/29/2024 | 58PCZ05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 5/6/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 5/6/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 5/6/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 5/6/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 5/6/2024 | 58PCZ05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 5/6/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 5/6/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 5/6/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 5/6/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 5/6/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 5/1/2024 | 65QCY02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/30/2024 | 58PCY05ONABOTULINUMTOXINA | Division of Southeast Imports (DSEI) | |
| 2/6/2024 | 65QCR02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/12/2024 | 65QDY02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/28/2023 | 65QDY02BOTOX | Division of Southeast Imports (DSEI) | |
| 5/3/2023 | 66VIY99MISCELLANEOUS PATENT MEDICINES, ETC. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/13/2023 | 65QIL02BOTOX | Division of West Coast Imports (DWCI) | |
| 4/6/2023 | 65QCL02BOTOX | Division of West Coast Imports (DWCI) | |
| 3/27/2023 | 65QBP02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/28/2023 | 65QCK02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/23/2022 | 65QCZ02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/14/2022 | 65QCY02BOTOX | 84RX DEVICE | Division of Southeast Imports (DSEI) |
| 11/18/2022 | 65QCP02BOTOX | Division of West Coast Imports (DWCI) | |
| 11/17/2022 | 65QCZ02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 11/3/2022 | 65QCY02BOTOX | Division of West Coast Imports (DWCI) | |
| 11/1/2022 | 65QCY02BOTOX | Division of Southeast Imports (DSEI) | |
| 10/24/2022 | 65QBY02BOTOX | Division of West Coast Imports (DWCI) | |
| 10/7/2022 | 65QCY02BOTOX | Division of Southeast Imports (DSEI) | |
| 10/7/2022 | 65QDZ02BOTOX | Division of Southeast Imports (DSEI) | |
| 8/30/2022 | 65KDL10BIMATOPROST (PROSTAGLANDIN) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 8/29/2022 | 65QCZ02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/30/2022 | 65QCK02BOTOX | Division of Southeast Imports (DSEI) | |
| 5/16/2022 | 79LMHIMPLANT, DERMAL, COLLAGEN FOR AESTHETIC USE | Division of Southeast Imports (DSEI) | |
| 5/10/2022 | 65QCK02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/6/2022 | 65QCK02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 5/5/2022 | 65QCK02BOTOX | Division of Southeast Imports (DSEI) | |
| 4/29/2022 | 65QDL02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/27/2022 | 65QCK02BOTOX | 3280FRNMFGREG | Division of Southeast Imports (DSEI) |
| 4/27/2022 | 65QCK02BOTOX | Division of Southeast Imports (DSEI) | |
| 4/18/2022 | 79LMHIMPLANT, DERMAL, COLLAGEN FOR AESTHETIC USE | 342PERSONALRX | Division of Southeast Imports (DSEI) |
| 4/4/2022 | 65QCY02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/1/2022 | 65QCY02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/25/2022 | 65QCL02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/11/2022 | 79LMHIMPLANT, DERMAL, COLLAGEN FOR AESTHETIC USE | Division of Southeast Imports (DSEI) | |
| 1/7/2022 | 65QCL02BOTOX | 342PERSONALRX | Division of Southeast Imports (DSEI) |
| 9/17/2021 | 65QDL02BOTOX | Division of Southeast Imports (DSEI) | |
| 9/3/2021 | 65QAY02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 8/27/2021 | 65QCK02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/30/2021 | 65QBY02BOTOX | Division of Southeast Imports (DSEI) | |
| 7/30/2021 | 65QCY02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 7/19/2021 | 65RAL99REPLENISHER N.E.C. | Division of Southeast Imports (DSEI) | |
| 7/6/2021 | 65QCY02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 2/26/2021 | 60QCY27THIAMYLAL SODIUM (ANESTHETIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 1/19/2021 | 65QCY02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/18/2020 | 65QBL02BOTOX | 71NO LICENSE | Division of Southeast Imports (DSEI) |
| 12/15/2020 | 65QAK02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 10/2/2020 | 65QDY02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 10/2/2020 | 65QDY02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/29/2020 | 65QCZ02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/29/2020 | 65QCZ02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/29/2020 | 65QCZ02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 9/3/2020 | 65QDL02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
Frequently Asked Questions
What is Allergan Pharmaceuticals Ireland's FDA import refusal history?
Allergan Pharmaceuticals Ireland (FEI: 3002806285) has 136 FDA import refusal record(s) in our database, spanning from 7/3/2003 to 11/17/2025.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Allergan Pharmaceuticals Ireland's FEI number is 3002806285.
What types of violations has Allergan Pharmaceuticals Ireland received?
Allergan Pharmaceuticals Ireland has been cited for 16 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about Allergan Pharmaceuticals Ireland come from?
All FDA import refusal data for Allergan Pharmaceuticals Ireland is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.